All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Ide-cel
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
The data from the study demonstrates deep and durable responses with ide-cel treatment in triple-class exposed RRMM patients. In the KarMMa study, ide-cel demonstrated a safety profile consistent with known toxicities of CAR T cell therapies, regardless of dose level.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tebentafusp
Therapeutic Area: Oncology Product Name: IMCgp100
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2021
Details:
FDA has granted Breakthrough Therapy Designation for tebentafusp based on the survival benefit from our Phase 3 clinical trial announced in November 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Durvalumab,Tremelimumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2021
Details:
KESTREL Phase III trial of Imfinzi (durvalumab) failed to meet the primary endpoint in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumours expressed high levels of PD-L1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tebentafusp
Therapeutic Area: Oncology Product Name: IMCgp100
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2021
Details:
Immunocore's pipeline contains its most advanced candidate, tebentafusp, which the company states has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 trial in previously untreated metastatic uveal melanoma.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
